ReNeuron Group PLC (LON:RENE) appointed life sciences industry veteran Iain Ross as chairman of the board with immediate effect.
Tim Corn is stepping down as chairman but will remain as a non-executive director.
READ: ReNeuron unveils new collaborations, data findings on exosome technology platform
Ross, whose role will also be non-executive, brings 40 years of experience in the international life sciences and technology sectors, including as chairman, chief executive and director of biotechnology companies including Celltech Group, Quadrant Healthcare and Redx Pharma. He is currently also non-executive chairman at Silence Therapeutics and Kazia Therapeutics.
ReNeuron chief executive Olav Hellebø said: “Iain has considerable experience with commercially successful international lifescience businesses and we welcome his support as we enter into a period where we expect to reach important, data-driven value inflection points across our programmes over the next 12 months.”
Ross added: “I am delighted to be joining ReNeuron at such a pivotal time and look forward to working with the board and management, and to ensuring a significant uplift in shareholder value over the next few years.”